NY officials consider blocking $69B CVS-Aetna merger

Amy Baxter | | Health Exec | Policy & Regulations
Manhattan, New York

Officials in New York state are reportedly considering blocking part of the ongoing merger between CVS Health and Aetna, according to Bloomberg.

The deal, worth $69 billion, has already received preliminary approval from the Department of Justice, with some contingencies, and was approved by regulators in Connecticut this week. The DOJ required that Aetna divest its Medicare Part D prescription drug plan in order for the deal to go through. WellCare Health Plans agreed to purchase Aetna’s Part D business in September.

The transaction still needs approval from state regulators, though executives from both companies expect the transaction will be completed before the end of the year.

The deal was the topic of a public hearing in Manhattan on Thursday, according to Bloomberg, with Superintendent of the Department of Financial Services Maria Vullo stating the agency may block the merger. She “repeatedly asked CVS and Aetna representatives for written evidence that they would deliver on promises to lower prices,” according to Bloomberg.

The deal has been met with some backlash from industry groups that argue the mega-merger will dampen competition.

See the full story below:

New York State Considers Blocking Parts of CVS-Aetna Merger

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Veterans Affairs denies it discriminates based on politics, marital status
Dexcom recalls more than 2 million CGM receivers over safety issues—dozens of adverse events reported
Ivenix infusion kits recalled by FDA due to serious manufacturing defect
FDA recalls pediatric breathing kits after eight serious injuries
Judge rips Trump administration for terminating DEI-advancing NIH grants: ‘Have we no shame?’
FDA recalls Zyno infusion pumps, citing risk of death

Around the web

Cardiovascular Business
Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

Cardiovascular Business
AMA House of Delegates helps cardiology groups influence healthcare policies

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.

Cardiovascular Business
Smaller revenues, less growth: In US, tariffs may create headaches for $34.5B cardiovascular device market

“Without a more concrete and stable policy on these tariffs from the current American administration, it is likely that most manufacturers will be forced to continuously change their internal forecasts and production plans," one analyst said.